Injectable treatment with cabotegravir and rilpivirine proved just as effective in maintaining viral suppression as standard oral antiretroviral treatment in a large trial in Africa, despite less intensive viral load monitoring than previous studies, Professor Nicholas Paton of the London School of Hygiene and Tropical Medicine reported at the Conference on Retroviruses and Opportunistic Infections in Denver on Monday.
The study is the first test of injectable treatment in people with HIV in Africa. The first injectable regimen, consisting of the integrase inhibitor cabotegravir and the non-nucleoside reverse transcriptase inhibitor (NNRTI) rilpivirine, is already approved for use in Europe and North America. Treatment is given by intramuscular injection at a health facility every two months.
Read the full story at Aidsmap.
Source : Aidsmap
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.